Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Tonix Pharmaceuticals Holding Corp

Healthcare US TNXP

12.75USD
-0.47(3.56%)

Last update at 2026-06-29T20:11:00Z

Day Range

12.5513.41
LowHigh

52 Week Range

0.122.10
LowHigh

Fundamentals

  • Previous Close 13.22
  • Market Cap16.24M
  • Volume524030
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-101.22100M
  • Revenue TTM10.25M
  • Revenue Per Share TTM0.29
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.7

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -110.21800M -92.28700M -50.46300M -28.61800M -26.08900M
Minority interest - - - - -
Net income -115.00400M -92.21200M -50.38800M -28.38200M -26.08900M
Selling general administrative 30.21M 23.47M 14.35M 10.64M 8.76M
Selling and marketing expenses - - - - -
Gross profit -112.09100M -92.31200M -50.51100M -28.82800M -26.32200M
Reconciled depreciation 1.25M 0.05M 0.03M 0.03M 0.05M
Ebit -113.34400M -92.36200M -50.53800M -28.85400M -26.37600M
Ebitda -112.09100M -92.31200M -50.51100M -28.82800M -26.32200M
Depreciation and amortization 1.25M 0.05M 0.03M 0.03M 0.05M
Non operating income net other - 0.03M 0.05M 0.21M 0.23M
Operating income -112.09100M -92.31200M -50.51100M -28.82800M -26.32200M
Other operating expenses 112.09M 92.31M 50.51M 28.83M 26.32M
Interest expense -7.91200M 0.05M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 1.87M 0.03M 0.05M 0.21M 0.23M
Net interest income 1.87M 0.03M 0.05M 0.21M 0.23M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.79M -0.07500M -0.07500M -0.23600M 0.23M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 112.09M 92.31M 50.51M 28.83M 26.32M
Cost of revenue 112.09M 92.31M 50.51M 28.83M 26.32M
Total other income expense net 1.87M 0.03M 0.05M 0.21M 0.23M
Discontinued operations - - - - -
Net income from continuing ops -110.21800M -92.28700M -50.46300M -28.61800M -26.08900M
Net income applicable to common shares -116.87700M -92.28700M -52.17400M -31.09200M -29.35500M
Preferred stock and other adjustments - - 1.26M 2.47M 3.27M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 154.46M 225.69M 240.90M 98.18M 14.56M
Intangible assets 9.74M - 0.12M 0.12M 0.12M
Earning assets - - - - -
Other current assets 4.08M 10.55M 10.39M 10.92M 2.70M
Total liab 48.93M 18.51M 22.18M 10.54M 5.14M
Total stockholder equity 105.53M 207.18M 218.72M 87.65M 9.42M
Deferred long term liab - - - - -
Other current liab 9.50M 6.41M 5.11M 2.46M 1.01M
Common stock 0.06M 0.08M 0.50M 0.21M 0.00900M
Capital stock 0.06M 0.08M 0.50M 0.21M 0.00900M
Retained earnings -600.65800M -470.03800M -359.82000M -267.53300M -217.07000M
Other liab - - 22.18M - 5.14M
Good will 0.96M - - - -
Other assets - 0.38M 51.85M 1.50M 0.10M
Cash 24.95M 120.23M 178.66M 77.07M 11.25M
Cash and equivalents - - - - -
Total current liabilities 18.88M 18.18M 21.72M 9.82M 5.13M
Current deferred revenue 2.98M 3.27M 2.83M 2.17M 0.70M
Net debt -15.13500M -119.46900M -177.70400M -75.75700M -10.89100M
Short term debt 2.62M 0.43M 0.49M 0.59M 0.35M
Short long term debt - - - - -
Short long term debt total 9.81M 0.76M 0.96M 1.31M 0.36M
Other stockholder equity 706.36M 677.31M 578.13M 355.04M 226.52M
Property plant equipment - 94.53M 51.47M 9.83M 0.03M
Total current assets 47.77M 130.78M 189.05M 87.99M 13.95M
Long term investments - - - - -
Net tangible assets - 207.18M 218.72M 87.53M 9.30M
Short term investments - - - - -
Net receivables 4.59M 8.04M 7.73M 7.63M 1.01M
Long term debt 6.56M - - - -
Inventory 14.15M -8.04300M -7.72600M -7.62700M -1.01100M
Accounts payable 3.78M 8.07M 13.28M 4.60M 3.07M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.23200M -0.16700M -0.09200M -0.06200M -0.04600M
Additional paid in capital - - - - -
Common stock total equity - - 0.50M 0.21M 0.00900M
Preferred stock total equity - - - - -
Retained earnings total equity - - -359.82000M -267.53300M -217.07000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -9.51400M 0.38M 0.26M 0.24M 0.10M
Deferred long term asset charges - - - - -
Non current assets total 106.69M 94.91M 51.85M 10.19M 0.61M
Capital lease obligations 0.90M 0.76M 0.96M 1.31M 0.36M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -48.14700M -35.30700M -8.56400M -0.01700M -0.00600M
Change to liabilities -1.04500M 3.53M 1.53M 2.12M 0.52M
Total cashflows from investing activities -48.14700M -35.30700M -8.56400M -0.01700M -0.00600M
Net borrowings - - - - -
Total cash from financing activities 87.84M 212.49M 123.11M 12.92M 23.54M
Change to operating activities 1.04M 2.25M -3.89400M -1.21100M 0.33M
Net income -110.21800M -92.28700M -50.46300M -28.61800M -26.08900M
Change in cash -58.43000M 101.59M 65.96M -13.78500M -0.45100M
Begin period cash flow 178.90M 77.31M 11.35M 25.13M 25.59M
End period cash flow 120.47M 178.90M 77.31M 11.35M 25.13M
Total cash from operating activities -98.05300M -75.55700M -48.56600M -26.68300M -23.97100M
Issuance of capital stock 135.05M 212.39M 113.21M 12.85M 23.54M
Depreciation 1.25M 0.05M 0.03M 0.03M 0.05M
Other cashflows from investing activities - - - - -
Dividends paid -6.65900M - -0.45100M -2.47400M 3.27M
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -47.25000M 3.00M 1.36M 12.92M 23.54M
Other cashflows from financing activities 47.29M -2.90200M 14.50M 9.52M 14.09M
Change to netincome 10.91M 10.90M 4.24M 1.46M 1.63M
Capital expenditures 48.15M 35.31M 8.56M 0.02M 0.00600M
Change receivables - - - - -
Cash flows other operating - 3.51M -5.44800M -1.67300M -0.07900M
Exchange rate changes - - - - -0.01300M
Cash and cash equivalents changes - 101.62M 65.97M -13.78100M -0.45100M
Change in working capital -0.00200M 5.78M -2.36600M 0.45M 0.44M
Stock based compensation 10.91M 7.90M 2.88M 1.46M 1.63M
Other non cash items - 3.00M 1.36M 15.04M 1.35M
Free cash flow -146.20000M -110.86400M -57.13000M -26.70000M -23.97700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TNXP
Tonix Pharmaceuticals Holding Corp		 -0.47 3.56% 12.75 - - 2.00 0.15 0.04 -0.0028
NVO
Novo Nordisk A/S		 0.27 0.56% 48.34 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.0025 0.0053% 47.56 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.31 1.69% 499.65 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -1.09 0.17% 631.81 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Tonix Pharmaceuticals Holding Corp

26 Main Street, Chatham, NJ, United States, 07928

Key Executives

Name Title Year Born
Dr. Daniel J. Clauw M.D. Consultant NA
Dr. Seth Lederman M.D. Co-Founder, Pres, CEO & Chairman 1958
Mr. Bradley Saenger CPA, CPA CFO & Treasurer 1974
Dr. Gregory M. Sullivan M.D. Chief Medical Officer & Sec. 1966
Mrs. Jessica Edgar Morris Chief Operating Officer NA
Dr. Herbert W. Harris M.D., Ph.D. Exec. VP of Translational Medicine NA
Dr. Bruce L. Daugherty M.B.A., Ph.D. Exec. VP of Research 1958
Ms. Siobhan Fogarty B.Sc., M.Sc. Exec. VP of Product Devel. NA
Dr. Darryl Rideout Ph.D. Exec. VP of Experimental Chemistry NA
Dr. Sina Bavari Ph.D. Exec. VP of Infectious Disease R&D NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.